Last reviewed · How we verify
Betamethasone 17-valerate 0.1% cream
Betamethasone 17-valerate 0.1% cream is a Topical corticosteroid (Class III/IV potency) Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis), Allergic contact dermatitis, Lichen planus.
Betamethasone 17-valerate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Betamethasone 17-valerate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis), Allergic contact dermatitis, Lichen planus.
At a glance
| Generic name | Betamethasone 17-valerate 0.1% cream |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Topical corticosteroid (Class III/IV potency) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Betamethasone 17-valerate is a synthetic glucocorticoid that penetrates the skin and binds to intracellular glucocorticoid receptors, leading to suppression of inflammatory mediators, reduced vasodilation, and decreased immune cell infiltration. This results in reduced erythema, pruritus, and other signs of cutaneous inflammation. The 17-valerate ester formulation enhances skin penetration and potency compared to the parent compound.
Approved indications
- Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis)
- Allergic contact dermatitis
- Lichen planus
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Systemic corticosteroid absorption (with prolonged use or occlusion)
Key clinical trials
- Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betamethasone 17-valerate 0.1% cream CI brief — competitive landscape report
- Betamethasone 17-valerate 0.1% cream updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Betamethasone 17-valerate 0.1% cream
What is Betamethasone 17-valerate 0.1% cream?
How does Betamethasone 17-valerate 0.1% cream work?
What is Betamethasone 17-valerate 0.1% cream used for?
Who makes Betamethasone 17-valerate 0.1% cream?
What drug class is Betamethasone 17-valerate 0.1% cream in?
What development phase is Betamethasone 17-valerate 0.1% cream in?
What are the side effects of Betamethasone 17-valerate 0.1% cream?
What does Betamethasone 17-valerate 0.1% cream target?
Related
- Drug class: All Topical corticosteroid (Class III/IV potency) drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis)
- Indication: Drugs for Allergic contact dermatitis
- Indication: Drugs for Lichen planus
- Compare: Betamethasone 17-valerate 0.1% cream vs similar drugs
- Pricing: Betamethasone 17-valerate 0.1% cream cost, discount & access